Valuation dashboard for PTC Therapeutics, Inc. (PTCT) with P/E N/A, P/B -29.74, EV/EBITDA 29.9 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications.
Analysis Summary
PTC Therapeutics, Inc. reported revenue of $1.73B in the most recent fiscal year, growing at a 5-year CAGR of 35.4%.
Trailing-twelve-month margins: gross margin 92.4%, operating margin 12.0%, net margin -9.2%.
At $68.12 (closing price, November 3, 2026), PTCT has negative trailing earnings (P/E not meaningful) and an ROE of 57.10%. Market capitalisation stands at $5.7B.
Balance sheet quality for PTCT: debt-to-equity ratio of -3.33, current ratio of 3.27 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | -29.74 |
| EV / EBITDA | 29.9 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| PTCT | PTC Therapeutics, Inc. | $5.7B | 57.1% | ||
| BBIO | BridgeBio Pharma, Inc. | $14.4B | 26.8% | ||
| IONS | Ionis Pharmaceuticals, Inc. | $6.7B | 15.21 | -110.8% | |
| BMRN | BioMarin Pharmaceutical Inc. | $10.8B | 1.72 | -0.3% | |
| KRYS | Krystal Biotech, Inc. | $9.0B | 41.39 | 6.29 | 17.0% |
| DYN | Dyne Therapeutics, Inc. | $3.4B | 4.25 | -64.3% |
Price
| Price | $68.12 (closing price, November 3, 2026) |
| Market Cap | $5.7B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 57.10% |
| Return on Invested Capital | 5.66% |
| Return on Assets | -3.30% |
| Gross Margin | 92.39% |
| Operating Margin | 11.97% |
| Net Margin | -9.17% |
Related companies: BBIO · IONS · BMRN · KRYS · DYN
Explore sector: Healthcare · Biotechnology
More sections of PTCT: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks